Company
Immunome
Reinventing Antibody - Drug Conjugates
Also known as Immunome Inc
- Business model
- B2B
- Legal name
- Immunome Inc
Claim, correct or request removal
Record updated 29 September 2026
About
We are a clinical-stage oncology company committed to developing best-in-class ADCs as well as other targeted therapies that improve outcomes for cancer patients.
Funding snapshot
- Total raised
- $71MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $27M2021-04-28
Funding rounds
- Round, 2021
- $27M2021-04-28, SEC form D sold, 47 investors
- Round, 2020
- $11M2020-06-02, SEC form D sold, 49 investors
- Round, 2019
- $9.3M2019-11-04, SEC form D sold, 35 investors
- Round, 2019
- $6.5M2019-02-07, SEC form D sold, 27 investors
- Round, 2017
- $5M2017-05-17, SEC form D sold, 48 investors
- Round, 2016
- $5.1M2016-07-01, SEC form D sold, 27 investors
- Round, 2015
- $3.6M2015-11-18, SEC form D sold, 18 investors
- Round, 2014
- $892K2014-09-30, SEC form D sold, 17 investors
- Round, 2014
- $735K2014-02-19, SEC form D sold, 23 investors
- Round, 2013
- $445K2013-02-08, SEC form D sold, 9 investors
- Round, 2012
- $145K2012-01-04, SEC form D sold, 4 investors
- Round, 2010
- $847K2010-04-19, SEC form D sold, 5 investors
- Round, 2009
- $435K2009-09-03, SEC form D sold, 6 investors
Loading relationship preview